+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Octapharma AG - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 34 Pages
  • June 2023
  • GlobalData
  • Octapharma AG
  • ID: 1291545
Octapharma AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The publisher's summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Octapharma AG (Octapharma) is a human protein product manufacturer that focuses on developing and producing medicines through human proteins from human plasma and cell lines. The company treats patients worldwide with products across immunotherapy, hematology, and critical care therapeutic areas. It sources plasma from company-owned plasma donation centers and other external sources. Octapharma owns plasma donation centers in the US and Germany and owns production facilities in Austria, Germany, France, Mexico, and Sweden. It’s production plants carry out plasma fractionation and purification, pharmaceutical production, research and development, product labeling, packaging, storage, and distribution. Octapharma is headquartered in Lachen, Switzerland.

Octapharma AG Key Recent Developments

  • Jun 06, 2023: Octapharma Presents New Data at ISTH 2023 in an Ongoing Commitment to Improve the Lives of People With Bleeding Disorders
  • Feb 02, 2023: European authorities approve lyophilized S/D treated plasma OctaplasLG for pre-hospital transfusion
  • Jan 24, 2022: As Omicron spreads nationally, Octapharma’s fibryga & Octaplas become increasingly important replacement therapies
  • Jan 19, 2022: Octapharma puts a spotlight on the challenges of managing inhibitors in haemophilia A at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the publisher's detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Octapharma AG - Key Facts
  • Octapharma AG - Key Employees
  • Octapharma AG - Major Products and Services
  • Octapharma AG - History
  • Octapharma AG - Company Statement
  • Octapharma AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Octapharma AG - Business Description
  • R&D Overview
  • Octapharma AG - Corporate Strategy
  • Octapharma AG - SWOT Analysis
  • SWOT Analysis - Overview
  • Octapharma AG - Strengths
  • Octapharma AG - Weaknesses
  • Octapharma AG - Opportunities
  • Octapharma AG - Threats
  • Octapharma AG - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Octapharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Octapharma AG, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Jun 06, 2023: Octapharma Presents New Data at ISTH 2023 in an Ongoing Commitment to Improve the Lives of People With Bleeding Disorders
  • Feb 02, 2023: European authorities approve lyophilized S/D treated plasma OctaplasLG for pre-hospital transfusion
  • Jan 24, 2022: As Omicron spreads nationally, Octapharma’s fibryga & Octaplas become increasingly important replacement therapies
  • Jan 19, 2022: Octapharma puts a spotlight on the challenges of managing inhibitors in haemophilia A at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
Section 5 - Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Octapharma AG, Key Facts
  • Octapharma AG, Key Employees
  • Octapharma AG, Major Products and Services
  • Octapharma AG, History
  • Octapharma AG, Other Locations
  • Octapharma AG, Subsidiaries
  • Octapharma AG, Key Competitors
  • Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Octapharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Octapharma AG, Recent Deals Summary
List of Figures
  • Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Octapharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Polyneuron Pharmaceuticals AG
  • Liminal BioSciences Inc
  • Abeona Therapeutics Inc
  • China Biologic Products Holdings Inc
  • Neurimmune Holding AG
  • Grifols USA LLC